Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
EVFM Evofem Biosciences
0.075
-0.007-8.54%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
50.24% -26.66M 39.29% -20.92M -39.91% -146.67M 45.58% -21.27M
Net income from continuing operations
-276.89% -125.98M 30.91% -31.89M -44.19% -205.19M -26.99% -51.55M
Operating gains losses
-- 70.84M -- 1.68M -- -- -- --
Depreciation and amortization
-9.09% 250K 35.90% 265K 238.74% 1.02M 135.54% 285K
Other non cash items
77.65% 1.49M -38.06% 918K 38.40% 4.07M -37.27% 882K
Change In working capital
71.85% -4.32M -15.68% 5.41M 169.47% 10.58M 373.38% 14.55M
-Change in receivables
-1,388.66% -2.89M 210.07% 2.03M -404.40% -5.38M -1,473.86% -2.42M
-Change in inventory
175.02% 787K 145.05% 755K 99.65% -21K 160.91% 1.89M
-Change in prepaid assets
89.35% -1.71M -107.61% -1.04M 179.98% 13.88M 261.67% 13.4M
-Change in payables and accrued expense
-176.12% -851K 5,430.30% 3.65M -20.25% 5.47M -38.95% 2.72M
-Change in other current liabilities
99.28% -3K -103.49% -466K -205.68% -1.51M -220.59% -436K
-Change in other working capital
-72.63% 347K 113.36% 469K -165.44% -1.86M -138.44% -600K
Cash from discontinued investing activities
Operating cash flow
50.24% -26.66M 39.29% -20.92M -39.91% -146.67M 45.58% -21.27M
Investing cash flow
Cash flow from continuing investing activities
87.25% -170K 90.65% -66K -143.17% -2.69M 96.27% -53K
Net PPE purchase and sale
87.25% -170K 93.10% -66K -30.39% -2.94M 96.27% -53K
Net business purchase and sale
-- 0 -- 0 0.00% 250K -- 0
Net investment purchase and sale
-- -- -- -- -- 0 -- 0
Cash from discontinued investing activities
Investing cash flow
87.25% -170K 90.65% -66K -143.17% -2.69M 96.27% -53K
Financing cash flow
Cash flow from continuing financing activities
-21.67% 41.36M -45.98% 15.13M -41.19% 90.69M -60.40% 9.87M
Net issuance payments of debt
-- -5.89M -- 10M -- 0 -- 0
Net common stock issuance
-49.85% 26.82M -80.46% 5.48M -24.17% 81.53M -- 0
Net preferred stock issuance
-- -- -- -- -- 10M -- --
Proceeds from stock option exercised by employees
-- -- -- -- 1.56% 456K -8.18% 101K
Net other financing activities
44.96% -508K -697.73% -351K 65.34% -1.3M -21.76% -235K
Cash from discontinued financing activities
Financing cash flow
-21.67% 41.36M -45.98% 15.13M -41.19% 90.69M -60.40% 9.87M
Net cash flow
Beginning cash position
-88.12% 7.73M -81.19% 13.59M 334.59% 72.25M -71.49% 25.04M
Current changes in cash
790.45% 14.53M 18.19% -5.86M -205.46% -58.66M 26.51% -11.45M
End cash Position
-64.65% 22.27M -88.12% 7.73M -81.19% 13.59M -81.19% 13.59M
Free cash flow
51.14% -26.83M 40.74% -20.99M -39.71% -149.61M 47.36% -21.32M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
CEO: Ms. Saundra Pelletier
Market: Pink Market
Listing Date: 11/20/2014
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist